Status: Not yet recruiting
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.
Participants needed: 94
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.Updated: Feb 12, 2026Locations: 1
Eligibility criteria
Subjects voluntarily sign the informed consent before the trial, and fully under... [+6]
Individuals with allergic constitution (allergic to multiple drugs and foods) or... [+19]